PAOG Breakout Alert - Sub Penny Ready To Breakthrough $0.01 On Cannabis Biotech News
January 27, 2021 -- via pennymillions
PAO Group, Inc. (PAOG)
started the day under $0.004 and has reached over $0.007 for a high
today. PAOG looks ready to reach over $0.01.
The stock was rated as a BUY today by AmericanBulls.com
The trading momentum comes after the company has announced
substantial progress developing its newly acquired cannabis
PAOG today announced next steps toward introducing a cannabis
nutraceutical to be distributed through North American Cannabis
Holdings, Inc. (USMJ) in addition to other distribution
Here is some background from a recent corporate update:
January 14, 2021
SANDUSKY, OH, Jan. 14, 2021 /PRNewswire/ -- PAO Group,
PAOG) today published a management outlook for 2021 on the
company's strategy to develop and monetize the cannabis assets
acquired last year. The strategic outlook is included in its
PAOG 2021 Cannabis Biopharmaceutical Strategic
PAOG is a longtime participant in the cannabis sector working on
initiatives to introduce cannabis treatments as alternatives to
traditional pharmaceuticals, particularly where existing
pharmaceutical treatments have potentially severe secondary
ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the
development biopharmaceutical treatments derived from cannabis.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc.
(OTC Pink: KALY) RespRx is a cannabis treatment under development
for Chronic Obstructive Pulmonary Disorder (COPD) derived from a
patented cannabis extraction method - U.S. Patent No. 9,199,960
entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT
MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG also acquired a of hemp cultivation business from Puration,
Inc. (USOTC: PURA). This operation comes with existing sales
activity and PAOG expects to report its first revenue from the
acquisition in conjunction with the inclusion of Q4 2020 results
into the overall 2020 financial report.
Since the two acquisitions, PAOG has been working diligently to
develop and execute upon a strategy to monetize the assets in a
manner that acheives self-sustainable operations at the same time
delivering optimal shareholder value.
Toward that end, PAOG has entered into three strategic
PAOG recently announced an engagement with Veristat, Inc., a
contract research organization headquartered in Southborough
Massachusetts. PAOG has engaged Veristat to assist in advancing
PAOG with its proprietary Cannabidiol (CBD) extract for the
treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward
initiating an Investigational New Drug application (IND) with the
Food and Drug Administration (FDA).
Veristat, a scientific-minded global clinical research
organization (CRO), enables sponsors to solve the unique and
complex challenges associated with accelerating therapies
development to regulatory
approval. With more than 26 years' experience in clinical trial
planning and execution, Veristat is equipped to support any
Learn more about Veristat at www.veristat.com.
PAOG management anticipates a pharmaceutical development process
to be a long-term endeavor. Management is committed to pursuing
complimentary initiatives that have the potential to deliver
revenue and profit in a shorter time frame.
PAOG has also recently engaged with the Puerto Rico Consortium
for Clinical Investigation to assist PAOG with developing its
proprietary Cannabidiol (CBD) extract into a nutraceutical product
to provide care for those experiencing issues associated with
Chronic Obstructive Pulmonary Disorder (COPD).
The Puerto Rico Consortium for Clinical Investigation (PRCCI) is
a not-for-profit network of top performing, high-quality research
sites invested in increasing the speed and quality of clinical
trials. PRCCI enhances clinical research speed and quality by
driving performance and efficiencies in research sites, leveraging
strategic partnerships and by establishing world-class
PAOG is targeting revenue in 2021 resulting from its
Learn more about PRCCI at www.prcci.org.
Source - https://www.pennymillions.com/blog/m4hmv79kr9y62k2v2ubrrtf5nt704u
Other stocks on the move included